Ikena Urges Shareholders to Support Merger with Inmagene
Deal News | Jul 11, 2025 | Globenewswire
Ikena Oncology has announced that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co. recommend that its shareholders vote in favor of issuing shares for a proposed merger with Inmagene Biopharmaceuticals. This proposed merger is set to be discussed at Ikena's upcoming Annual Meeting of Stockholders on July 15, 2025. Inmagene is a clinical-stage biotech company focusing on therapies for immunological and inflammatory diseases and has made significant advances, including IMG-007, a novel therapeutic. Mark Manfredi, CEO of Ikena, emphasized the potential for IMG-007 to build shareholder value. The merger includes issuing new shares as part of Proposal 1 and forms part of broader considerations at the annual meeting. Voting is open to all stockholders of record as of May 22, 2025. Forward-looking statements discuss potential benefits and risks associated with the merger, such as regulatory approvals and market conditions. This announcement stresses the importance of participation by shareholders and provides further details on accessing relevant filings and more information through Ikena’s and the SEC's websites.
Sectors
- Biotechnology
- Pharmaceuticals
- Financial Services
Geography
- United States – Ikena Oncology is a U.S.-based company and the shareholder meeting and voting process discussed is governed by U.S. regulations.
Industry
- Biotechnology – The article discusses Ikena Oncology and Inmagene Biopharmaceuticals, which are biotechnology firms focused on developing novel therapeutics for diseases.
- Pharmaceuticals – Inmagene is developing drug candidates like IMG-007 for immunological and inflammatory diseases, which falls under the pharmaceutical sector.
- Financial Services – The involvement of ISS and Glass Lewis, as well as the shareholder vote, positions this article also within the financial services sector.
Financials
- – The article does not specify a deal price or specific financials pertaining to the merger.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Ikena Oncology | Target Company | Company | Ikena Oncology develops differentiated therapies targeting cancer growth, spread, and therapeutic resistance. |
| Inmagene Biopharmaceuticals | Bidding Company | Company | Inmagene is a privately-owned biotechnology company focused on novel therapeutics for immunological and inflammatory diseases. |
| Institutional Shareholder Services Inc. | Advisory Firm | Company | ISS is a leading provider of corporate governance and responsible investment solutions for organizations. |
| Glass, Lewis & Co. | Advisory Firm | Company | Glass Lewis is a leading independent provider of global governance services, helping institutional investors understand and connect with their companies. |
| Mark Manfredi | CEO of Ikena | Person | Chief Executive Officer of Ikena, provided statements on the potential of the merger with Inmagene. |